Enhanced endometrial proliferation correlates obesity to type-I (estrogen-dependent) endometrial cancer (EC). Our aim was to distinguish obese women (without EC) with differing endometrial proliferation. Endometrial and blood samples were obtained from normal-weight and obese women without EC. Type-I EC samples were obtained from obese patients. On measuring endometrial proliferation (Ki67 and phosphorylated histone H3 (p-H3)), two groups of obese women without EC were identified: obese High Proliferating (O HP ) and obese Low Proliferating (O LP ). Increased Ki67 (88.5%, Po0.001), p-H3 (62.6%, Po0.01), 17b-estradiol/ progesterone ratio (46.3%, Po0.01) and endometrial estrogen receptor alpha (ERa) (82.2%, Po0.001) were observed in O HP compared with O LP patients. ECs possessed similar ERa and enhanced proliferation as O HP , suggesting that O HP women are at higher risk of type-I EC. O LP women were indistinguishable from normal-weight women regarding these determinants of endometrial proliferation, ERa and 17b-estradiol/progesterone ratio. Our data may further define the obesity phenotype in regards to type-I EC risk and may help identify obese women more susceptible to develop type-I EC, allowing early intervention and a potential reduction in mortality.
INTRODUCTION
Over the past decade, the prevalence of obesity has increased worldwide at alarming rates. 1 Now classified as a global epidemic, there are currently more than 1 billion overweight adults and at least 300 million obese patients. 2 Type-I (estrogen-dependent) endometrial cancer (EC) was the first to be recognized as being linked to obesity, delivering a 3.5-fold increased risk. 3, 4 The percentage of EC cases attributed to excess body weight among both pre-and postmenopausal women is growing, with recent estimates suggesting that 70 --90% of EC patients are obese. 5 High estrogen levels unopposed by progesterone have been associated with increased type-I EC risk. 6 One of the proposed mechanisms is that estrogen, via the estrogen receptor (ER), 7 induces endometrial cell proliferation, therefore increasing the probability of mutations and the chance for malignant transformation. 8 Approximately 20% of the patients with EC die as a result of their disease. 9 This situation may reflect the failure of current diagnostics to identify early stages. Moreover, it has been a medical paradigm that not all obese women develop type-I EC, thus, it is paramount to identify these women at higher risk to enable vigilance and timely intervention to reduce EC mortality. Therefore, we propose the existence of two subgroups of obese women without EC, with differing endometrial proliferation levels and differing potential risks for developing EC. Here we examined circulating levels of steroids, endometrial estrogen receptor alpha (ERa), and markers of epithelial endometrial cells proliferation Ki67 and phosphorylated histone H3 (p-H3) in serum and endometrial samples obtained from normal-weight women and obese patients with normal endometrial histology, and from obese women with type-I EC.
MATERIALS AND METHODS

Human subjects
Blood and endometrial samples were obtained during the proliferative phase of the menstrual cycle from cycling pre-menopausal women undergoing routine hysterectomy to treat leiomyomas with conserved endometrial cavity at the San Borja-Arriarán Clinical Hospital, Santiago, Chile. Specimens were collected by an experienced histopathologist from the fundus and corpus of the uterus by curettage of the endometrial tissue. The proliferative phase was confirmed according to the histological criteria described by Noyes. 10 The groups were defined according to the body mass index (BMI) as follows:
11 normal-weight group (BMI ¼ 18 --24.9 kg/m 2 , n ¼ 10) and obese group (BMIX30 kg/m 2 , n ¼ 20). Obese patients were subdivided into two groups according to our determinations of endometrial proliferation such as immunostaining for Ki67 and p-H3. None of the women received hormonal therapy or other medications within 3 months before recruitment into the study, and all endometrial tissue used (from premenopausal women) showed normal morphology.
A total of 12 postmenopausal obese patients with type-I EC were recruited from Dr Luis Tisné Hospital, Santiago, Chile.
No patients included in the present study had a clinical or familial history of diabetes, thyroid problems or polycystic ovary syndrome, and all were non-smokers. The clinical and endocrinological characteristics of the subjects are shown in Table 1 . Institutional and Health Service Review Boards approved this study before its execution. Informed written consent was obtained before surgery for all patients.
Laboratory measurements
Serum estradiol (E 2 ), estrone (E 1 ), testosterone (T), androstenedione (A 4 ) and progesterone (P 4 ) levels were determined by radioimmunoassay (Diagnostic System Laboratories, Webster, TX, USA); sex hormone-binding globulin concentration by immunoradiometric assay (DPC, Los Angeles, CA, USA).
Immunohistochemistry
Immunostaining for Ki67 and p-H3 was performed on sections of formalinfixed paraffin-embedded endometrial samples, as described previously. 12 Immunohistochemical evaluation was determined as the percentage of positive epithelial cells by three independent observers and blinded to patient category, and the positive staining was assessed in at least 2000 cells per sample.
Western blotting
ERa-protein expression was examined in fresh tissue specimens as described previously. 13 Separate western blots were performed on each patient sample, and the samples were not pooled. Band intensity was quantified by scanning densitometry utilizing the UN-SCAN-IT software, Automated Digitizing System, Version 5.1 (Silk Scientific Inc., Orem, UT, USA).
Statistical analysis
One-way ANOVA test was used followed by Tukey's post-hoc test. P-values o0.05 were considered significant. Statistical tests were performed using SPSS for Windows version 10.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
We identified two groups of obese patients with high and low levels of epithelial cell proliferation. Endometrial proliferation was evaluated by the Ki67 antigen (a marker for the proliferative state of the cells expressed in G1, S, G2 and M phases of the cell cycle) and p-H3 protein (expressed during the M phase of the cell cycle) in samples obtained from women with normal or obese BMIs. Both proteins were expressed in the nucleus of epithelial cells in the groups under study (Figures 1A, a --h). Obese subjects with high levels of Ki67 and p-H3 were classified as obese High Proliferating (O HP ) (n ¼ 14), whereas obese individuals with low levels of Ki67 and p-H3 were classified as obese Low Proliferating (O LP ) (n ¼ 6). Specifically, the expression of Ki67 in endometrial epithelial cells was found to be 88.5% higher (Po0.001) in the O HP group with respect to the O LP group ( Figure 1B) . Similarly, we detected 62.6% greater levels (Po0.01) in p-H3 expression in the O HP group compared with O LP subjects ( Figure 1C) . With respect to endometrial cell proliferation, the O LP group did not differ from normal-weight women ( Figures 1B and C) . A significantly higher percentage of epithelial cells with positive staining for Ki67 and p-H3 were detected in women with EC compared with women with normal endometrial histology ( Figures 1B and C) .
On examination of the clinical and endocrinological characteristics of the two obese groups (Table 1) , the most intriguing observation was that no significant differences were found in age, body weight, BMI, waist circumference, waist-to-hip ratio, serum androgens or sex hormone-binding globulin, yet, the circulating-E 2 /P 4 levels were significantly elevated in the O HP (46.3%, Po0.01), as compared with the O LP group (Table 1) . Furthermore, significantly higher ERa expression (82.2%) was observed in the endometria obtained from the O HP group with respect to the O LP group (Po0.001), and no differences were observed between the O HP and EC groups ( Figure 1D ). The O LP group did not differ from normal-weight women regarding endometrial ERa expression or serum E 2 /P 4 levels. The clinical and endocrinological characteristics of the obese patients with EC, were inherent to their postmenopausal status.
DISCUSSION
The human endometrium is a dynamic tissue, undergoing proliferative and secretory changes that are primarily mediated by the ratio of the hormones E 2 and P 4 . Obesity has been reported to alter the serum levels of these sex hormones, thus increasing type-I EC risk. 3 We recently have demonstrated the correlation between obesity, increased endometrial cell proliferation and the activation The intra-and interassay coefficients of variation of the hormonal measurements were 3.2% and 6.1%, respectively, for A 4 ; 7.0% and 11% for T; 3.9% and 6.9% for SHBG; 4.1% and 6.7% for E 2 ; 8.4% and 9.1% for E 1 ; and 4.8% and 7.2% for P 4 .
of AKT and ERK1/2, suggesting that these features could be related to a higher risk of developing type-I EC in premenopausal obese women. 12 The current study identifies obese premenopausal women with high (O HP group) and low (O LP group) levels of endometrial cell proliferation. Interestingly, the O LP group did not differ from normal-weight women with respect to endometrial proliferation.
We propose that the O HP obesity condition could provide an opportunity for the endometrial cells to escape normal proliferative control, accumulate mutations and become neoplastic at a later stage. Given this, it is relevant that the O HP endometrial proliferation observed herein is similar to that observed in obese women with EC. Moreover, this could have further consequence, as menopause may occur later in obese women, thus these women have more years of estrogen exposure.
14 However, it is unclear why a subset of obese individuals does not appear to suffer the consequences of obesity-related EC. Herein, we show that the O LP group has similar serum levels of unopposed E 2 and endometrial ERa as the normal-weight set, suggesting that this may be the group that accounts for this lower incidence subset. In contrast, the O HP group showed increased serum levels of E 2 , a higher E 2 /P 4 ratio and high endometrial expression of ERa (similar to the level of ERa expression in obese women with EC). The high E 2 /P 4 ratio found in O HP women could exert a stronger influence on endometrial proliferation in these subjects.
High serum E 2 levels among obese women and its association with EC risk have been reported previously; 15, 16 however, this is the first report that identifies a subgroup of obese women with levels of circulating E 2 /P 4 , endometrial expression of ERa, and cellular proliferation similar to the control group. A follow-up study will be needed to verify our hypothesis regarding the lower risk for developing type-I EC in women with the endocrinological features reported here for the O LP group. A possibility is that differences in steroid metabolic enzymes modifies conversion of steroids and thus explains the higher or lower proliferation found, in comparison with the O HP and the O LP group. Studies to test this possibility are currently in process, however, the results fall outside the scope of this initial report.
Herein, we present a population size adequate to postulate the presence of subgroups of obese patients. However, despite a global association between obesity and EC risk, a limitation of our study is the relatively small genetic and population diversity present because of patient recruitment originating principally from one recruitment area. Our initial observation is hopefully the first step for larger studies that could confirm these findings and allow multivariate analysis for parameters not considered herein because of insufficient sample size. Among these many variables are lifestyle factors, the age of onset of obesity, the extent of physical exercise performed by each patient and the metabolic profile.
Evidence-based literature suggests the existence of metabolically healthy, but obese individuals that may represent up to 20% of the obese population. 17, 18 However, despite these reports, there has been an inability to adequately determine or characterize factors that distinguish obese subgroups. With a greater population size and multivariate analysis, it will be interesting to ascertain whether the reported metabolically healthy, but obese subgroup either corresponds to, or has similarities to the endometrial subgroup described herein. A connection between metabolic prolife and circulating-estrogen levels is already established and thus, it is more than feasible to speculate an overlap between metabolically healthy, but obese patients and obese patients clustered by endometrial proliferation. 19 Given that our data may further define the obesity phenotype in regards to the risk for type-I EC development, our definition of O HP women could have a substantial public health value. New tools to identify obese women who are more susceptible to develop EC could eventually lead to early interventions and reduce the need for highly invasive surgery, which will impair the woman's reproductive capacity and reduce her quality of life. These early interventions include behavioral (diet and exercise), surgical (metabolic/bariatric surgery) and pharmaceutical (use of metformin) interventions that could prevent or reverse the hormonal and metabolic imbalances associated with obesity. Weight loss by dietary changes or exercise or a combination of both reduces estrogen synthesis and specifically high-fiber low-fat diet interventions have been shown to lower the bioavailable concentration of E 2 . 20, 21 Unfortunately, the significant lifestyle changes that are associated with weight loss are difficult to adopt and maintain. An alternative is bariatric surgery, which has recently been demonstrated to reduce EC risk. 22, 23 The antidiabetic drug Metformin may be a viable option for the prevention of EC in obese women, as this drug has been shown to inhibit aromatase expression 24 and increase progesterone receptor levels in EC cell lines. 25 An enhanced understanding of obesity subtypes may help guide primary and secondary prevention efforts for both metabolic disorders and cancer risk, with the ultimate aims of increasing quality of life and reducing mortality.
